CDC Suspends Some Research At Texas A&M

By: Pachatta Pope Email
By: Pachatta Pope Email

Texas A&M University Interim President Eddie J. Davis released a statement regarding another site visit by CDC officials concerning the university’s work with select agents and toxins.

“We have just received a memorandum from the Centers for Disease Control and Prevention (CDC) notifying us of the suspension of our work with select agents and toxins pending the outcome of another site visit by CDC representatives, scheduled between July 9 and 23. Suffice it to say that we take this matter very seriously and are committed to taking all appropriate steps to ensure that we are in full compliance with all CDC and any other relevant policies and regulations. In fact, we have already strengthened our safety, training and reporting procedures. We plan to cooperate fully with the CDC and look forward to resolving this matter in an appropriate manner as quickly as possible so that we can move forward in our work supporting the nation’s homeland defense initiatives.”

Join the Conversation!

To comment, the following rules must be followed:

  • No Obscenity, Profanity, Vulgarity, Racism or Violent Descriptions
  • No Negative Community Comparisons
  • No Fighting, Name-calling, Trolling or Personal Attacks
  • Multiple Accounts are Not Allowed
  • Stay on Story Topic

Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.

Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Questions may be sent to Please provide detailed information.

powered by Disqus
KBTX-TV Channel 3 4141 E. 29th Street Bryan, TX 77802 Phone: (979) 846-7777 Fax: (979) 846-1490 News Fax: (979) 846-1888
Copyright © 2002-2015 - Designed by Gray Digital Media - Powered by Clickability 8274412 -
Gray Television, Inc.